Viewpoint News & Awards

MARCH 15, 2021

Viewpoint Molecular Targeting™ Establishes Strategic Manufacturing Supply Agreement with Industry-Leader, SpectronRx, to Accelerate Build-Out of Ra-224/Pb-212 Generator (VMT-𝛼-GEN) Production Facilities

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s leading alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enabling the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.